Published in Biochemistry on January 23, 2007
HIV-1 Integrase Binds the Viral RNA Genome and Is Essential during Virion Morphogenesis. Cell (2016) 1.41
Simultaneous recognition of HIV-1 TAR RNA bulge and loop sequences by cyclic peptide mimics of Tat protein. Proc Natl Acad Sci U S A (2009) 1.33
How binding of small molecule and peptide ligands to HIV-1 TAR alters the RNA motional landscape. Nucleic Acids Res (2009) 1.20
γ-AApeptides bind to RNA by mimicking RNA-binding proteins. Org Biomol Chem (2011) 1.06
Discovering ligands for a microRNA precursor with peptoid microarrays. Nucleic Acids Res (2009) 1.04
Essential structural requirements for specific recognition of HIV TAR RNA by peptide mimetics of Tat protein. Nucleic Acids Res (2010) 1.00
Inhibition of both HIV-1 reverse transcription and gene expression by a cyclic peptide that binds the Tat-transactivating response element (TAR) RNA. PLoS Pathog (2011) 0.97
Click dimers to target HIV TAR RNA conformation. Biochemistry (2012) 0.97
Toward targeting RNA structure: branched peptides as cell-permeable ligands to TAR RNA. ACS Chem Biol (2011) 0.95
Design of beta-hairpin peptidomimetics that inhibit binding of alpha-helical HIV-1 Rev protein to the rev response element RNA. Angew Chem Int Ed Engl (2007) 0.95
Cyclic peptides as therapeutic agents and biochemical tools. Biomol Ther (Seoul) (2012) 0.94
Recognition of HIV TAR RNA by triazole linked neomycin dimers. Bioorg Med Chem Lett (2011) 0.91
Methods to enable the design of bioactive small molecules targeting RNA. Org Biomol Chem (2014) 0.86
Recognition of HIV-TAR RNA using neomycin-benzimidazole conjugates. Bioorg Med Chem Lett (2013) 0.85
Giant macrolactams based on β-sheet peptides. J Org Chem (2011) 0.85
N-Methylation as a Strategy for Enhancing the Affinity and Selectivity of RNA-binding Peptides: Application to the HIV-1 Frameshift-Stimulating RNA. ACS Chem Biol (2015) 0.82
Retracted Selection of cyclic peptide aptamers to HCV IRES RNA using mRNA display. Proc Natl Acad Sci U S A (2008) 0.78
Max Bergmann lecture protein epitope mimetics in the age of structural vaccinology. J Pept Sci (2013) 0.78
Multivalency in the recognition and antagonism of a HIV TAR RNA-TAT assembly using an aminoglycoside benzimidazole scaffold. Org Biomol Chem (2016) 0.77
Bovine immunodeficiency virus: a lentiviral infection. Indian J Virol (2013) 0.76
Approaches to Validate and Manipulate RNA Targets with Small Molecules in Cells. Annu Rev Pharmacol Toxicol (2015) 0.75
Defining RNA-Small Molecule Affinity Landscapes Enables Design of a Small Molecule Inhibitor of an Oncogenic Noncoding RNA. ACS Cent Sci (2017) 0.75
Multivalent Amino Sugars to Recognize Different TAR RNA Conformations. Medchemcomm (2014) 0.75
Design of a novel globular protein fold with atomic-level accuracy. Science (2003) 13.06
RNA-binding proteins: modular design for efficient function. Nat Rev Mol Cell Biol (2007) 5.33
High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res (2003) 3.48
The structure and function of small nucleolar ribonucleoproteins. Nucleic Acids Res (2007) 2.50
Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa. Science (2010) 2.49
Strong correlation between SHAPE chemistry and the generalized NMR order parameter (S2) in RNA. J Am Chem Soc (2008) 2.26
Cell growth regulatory role of Runx2 during proliferative expansion of preosteoblasts. Cancer Res (2003) 2.20
Recognition of GU-rich polyadenylation regulatory elements by human CstF-64 protein. EMBO J (2003) 2.01
Protein families and RNA recognition. FEBS J (2005) 1.65
The Cbf5-Nop10 complex is a molecular bracket that organizes box H/ACA RNPs. Nat Struct Mol Biol (2005) 1.52
High-resolution structural and thermodynamic analysis of extreme stabilization of human procarboxypeptidase by computational protein design. J Mol Biol (2006) 1.49
Structure of stem-loop IV of Tetrahymena telomerase RNA. EMBO J (2006) 1.49
The highly cooperative folding of small naturally occurring proteins is likely the result of natural selection. Cell (2007) 1.46
Rational design of inhibitors of HIV-1 TAR RNA through the stabilisation of electrostatic "hot spots". J Mol Biol (2004) 1.37
Simultaneous recognition of HIV-1 TAR RNA bulge and loop sequences by cyclic peptide mimics of Tat protein. Proc Natl Acad Sci U S A (2009) 1.33
Cooperative interaction of transcription termination factors with the RNA polymerase II C-terminal domain. Nat Struct Mol Biol (2010) 1.32
A conserved RNA structure within the HCV IRES eIF3-binding site. Nat Struct Biol (2002) 1.31
An all-atom, distance-dependent scoring function for the prediction of protein-DNA interactions from structure. Proteins (2007) 1.28
Structural genomics of infectious disease drug targets: the SSGCID. Acta Crystallogr Sect F Struct Biol Cryst Commun (2011) 1.27
A new hydrogen-bonding potential for the design of protein-RNA interactions predicts specific contacts and discriminates decoys. Nucleic Acids Res (2004) 1.27
A knowledge-based potential function predicts the specificity and relative binding energy of RNA-binding proteins. FEBS J (2007) 1.26
NMR studies of dynamics in RNA and DNA by 13C relaxation. Biopolymers (2007) 1.24
Induction of parasite growth-inhibitory antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of Plasmodium falciparum apical membrane antigen 1. Infect Immun (2003) 1.20
How binding of small molecule and peptide ligands to HIV-1 TAR alters the RNA motional landscape. Nucleic Acids Res (2009) 1.20
The C-terminal domains of vertebrate CstF-64 and its yeast orthologue Rna15 form a new structure critical for mRNA 3'-end processing. J Biol Chem (2006) 1.20
Real-time multidimensional NMR follows RNA folding with second resolution. Proc Natl Acad Sci U S A (2010) 1.18
13C NMR relaxation studies of RNA base and ribose nuclei reveal a complex pattern of motions in the RNA binding site for human U1A protein. J Mol Biol (2005) 1.18
Hydration dependent dynamics in RNA. J Biomol NMR (2009) 1.17
Crystal structure of OxyB, a cytochrome P450 implicated in an oxidative phenol coupling reaction during vancomycin biosynthesis. J Biol Chem (2002) 1.16
Using a beta-hairpin to mimic an alpha-helix: cyclic peptidomimetic inhibitors of the p53-HDM2 protein-protein interaction. Angew Chem Int Ed Engl (2004) 1.16
A new alpha-helical extension promotes RNA binding by the dsRBD of Rnt1p RNAse III. EMBO J (2004) 1.12
Discovery of novel, highly potent and selective beta-hairpin mimetic CXCR4 inhibitors with excellent anti-HIV activity and pharmacokinetic profiles. Bioorg Med Chem (2006) 1.11
Structural mimicry of retroviral tat proteins by constrained beta-hairpin peptidomimetics: ligands with high affinity and selectivity for viral TAR RNA regulatory elements. J Am Chem Soc (2004) 1.11
TAR RNA recognition by a cyclic peptidomimetic of Tat protein. Biochemistry (2005) 1.09
The design, structures and therapeutic potential of protein epitope mimetics. Drug Discov Today (2008) 1.07
Structure and stability of wild-type and mutant RNA internal loops from the SL-1 domain of the HIV-1 packaging signal. J Mol Biol (2002) 1.07
How arginine-rich domains coordinate mRNA maturation events. RNA Biol (2007) 1.07
Protein and RNA dynamics play key roles in determining the specific recognition of GU-rich polyadenylation regulatory elements by human Cstf-64 protein. J Mol Biol (2005) 1.07
Oxidative phenol coupling reactions catalyzed by OxyB: a cytochrome P450 from the vancomycin producing organism. implications for vancomycin biosynthesis. J Am Chem Soc (2007) 1.07
The solution structure of an essential stem-loop of human telomerase RNA. Nucleic Acids Res (2003) 1.06
Structural basis for stabilization of the tau pre-mRNA splicing regulatory element by novantrone (mitoxantrone). Chem Biol (2009) 1.06
The structure of an enzyme-activating fragment of human telomerase RNA. RNA (2005) 1.06
Engineering RNA-binding proteins for biology. FEBS J (2013) 1.06
γ-AApeptides bind to RNA by mimicking RNA-binding proteins. Org Biomol Chem (2011) 1.06
Validation of automated docking programs for docking and database screening against RNA drug targets. J Med Chem (2004) 1.05
Crystal structure of OxyC, a cytochrome P450 implicated in an oxidative C-C coupling reaction during vancomycin biosynthesis. J Biol Chem (2003) 1.05
Binding of U1A protein changes RNA dynamics as observed by 13C NMR relaxation studies. Biochemistry (2007) 1.05
Solid-state deuterium NMR studies reveal micros-ns motions in the HIV-1 transactivation response RNA recognition site. J Am Chem Soc (2008) 1.05
Structure-activity studies in a family of beta-hairpin protein epitope mimetic inhibitors of the p53-HDM2 protein-protein interaction. Chembiochem (2006) 1.04
An oxidative phenol coupling reaction catalyzed by oxyB, a cytochrome P450 from the vancomycin-producing microorganism. Angew Chem Int Ed Engl (2004) 1.01
Synthetic virus-like particles from self-assembling coiled-coil lipopeptides and their use in antigen display to the immune system. Angew Chem Int Ed Engl (2007) 1.01
Essential structural requirements for specific recognition of HIV TAR RNA by peptide mimetics of Tat protein. Nucleic Acids Res (2010) 1.00
Novel protein-protein contacts facilitate mRNA 3'-processing signal recognition by Rna15 and Hrp1. J Mol Biol (2010) 1.00
The box H/ACA RNP assembly factor Naf1p contains a domain homologous to Gar1p mediating its interaction with Cbf5p. J Mol Biol (2007) 0.99
Protein ligand design: from phage display to synthetic protein epitope mimetics in human antibody Fc-binding peptidomimetics. J Am Chem Soc (2006) 0.97
LPA induces osteoblast differentiation through interplay of two receptors: LPA1 and LPA4. J Cell Biochem (2010) 0.97
Inhibition of both HIV-1 reverse transcription and gene expression by a cyclic peptide that binds the Tat-transactivating response element (TAR) RNA. PLoS Pathog (2011) 0.97
Inhibition of lipopolysaccharide transport to the outer membrane in Pseudomonas aeruginosa by peptidomimetic antibiotics. Chembiochem (2012) 0.96
High-resolution structural validation of the computational redesign of human U1A protein. Structure (2006) 0.96
Design of beta-hairpin peptidomimetics that inhibit binding of alpha-helical HIV-1 Rev protein to the rev response element RNA. Angew Chem Int Ed Engl (2007) 0.95
Structure-activity-based design of a synthetic malaria peptide eliciting sporozoite inhibitory antibodies in a virosomal formulation. Chem Biol (2007) 0.94
Mitoxantrone analogues as ligands for a stem-loop structure of tau pre-mRNA. J Med Chem (2009) 0.94
Monitoring tat peptide binding to TAR RNA by solid-state 31P-19F REDOR NMR. Nucleic Acids Res (2005) 0.94
Cell-free production of functional Plasmodium falciparum dihydrofolate reductase-thymidylate synthase. Mol Biochem Parasitol (2006) 0.93
Mis-translation of a computationally designed protein yields an exceptionally stable homodimer: implications for protein engineering and evolution. J Mol Biol (2006) 0.93
Structure of the yeast SR protein Npl3 and Interaction with mRNA 3'-end processing signals. J Mol Biol (2007) 0.93
Crystal structure of an NPNA-repeat motif from the circumsporozoite protein of the malaria parasite Plasmodium falciparum. Chem Commun (Camb) (2005) 0.92
Antibodies elicited by a virosomally formulated Plasmodium falciparum serine repeat antigen-5 derived peptide detect the processed 47 kDa fragment both in sporozoites and merozoites. Peptides (2007) 0.92
13C relaxation studies of the DNA target sequence for hhai methyltransferase reveal unique motional properties. Biochemistry (2008) 0.91
The structure of a Burkholderia pseudomallei immunophilin-inhibitor complex reveals new approaches to antimicrobial development. Biochem J (2011) 0.91
Theory of nonrigid rotational motion applied to NMR relaxation in RNA. J Phys Chem A (2011) 0.91
Engineered synthetic virus-like particles and their use in vaccine delivery. Chembiochem (2011) 0.90
Intermediate rate atomic trajectories of RNA by solid-state NMR spectroscopy. J Am Chem Soc (2010) 0.89
A model for C74 addition by CCA-adding enzymes: C74 addition, like C75 and A76 addition, does not involve tRNA translocation. J Biol Chem (2006) 0.89
Synthesis, solution structure and immune recognition of an epidermal growth factor-like domain from Plasmodium falciparum merozoite surface protein-1. Chembiochem (2006) 0.89
A virosomal malaria peptide vaccine elicits a long-lasting sporozoite-inhibitory antibody response in a phase 1a clinical trial. PLoS One (2007) 0.89
A virosome-mimotope approach to synthetic vaccine design and optimization: synthesis, conformation, and immune recognition of a potential malaria-vaccine candidate. Angew Chem Int Ed Engl (2003) 0.87